Abstract: A cardiomyocyte maturation medium comprises a base medium, one or more fatty acids such as palmitic acid, glucose and albumin. The one or more fatty acids and glucose are ideally present at a concentration ratio of about 1:10. Typically, the medium does not comprise TGF or insulin, or comprises minimal TGF and/or insulin. A cell culture vessel is provided that comprises opposed poles that facilitate force measurements of developing cardiac muscle.

Abstract: An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens.

Abstract: Disclosed are compositions and methods for targeted treatment of cancer, such as HPV-associated cancer. In particular, modified T cell receptor (TCR) T cells are disclosed that can be used with adoptive cell transfer to target and kill cancer cells with reduced antigen escape. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with HPV-associated cancer that involves adoptive transfer of the disclosed TCR-T cells.

Abstract: Disclosed are compounds for use in modulating immune responses. More particularly, the present invention discloses oligomeric forms of PD-L2 for use in modulating Th1 immune responses. The compounds of the present invention find utility in a range of Th1-mediated disorders including pathogenic infections and hyperproliferative disorders.

Abstract: Disclosed is a human herpesvirus immunotherapy. More particularly, disclosed is a composition that includes one or more recombinant proteins that include a plurality of epitopes derived from multiple human cytomegalovirus antigens, a CMV envelope5glycoprotein, and a TLR agonist.

Abstract: Disclosed are methods of identifying immunosuppressive TR1 regulatory T cells, including in methods of diagnosing the presence of immune tolerance, methods of producing immunosuppressive regulatory T cells, and methods of eliciting immune tolerance in a subject. These methods include screening T cells to detect Eomes+IL-10+ T cells or expressing recombinant Eomes in T cell populations to generate immunosuppressive regulatory T cells.

Abstract: Provided herein are compositions and methods related to a multivirus-specific T cell immunotherapy.

Abstract: The present disclosure relates to the production of transmissible vims defective interfering particles (DIPs), particularly those of dengue virus as well as methods of their production. The DIPs have particular utility as immunogenic compositions and vaccines.

Abstract: Described herein are methods of protecting and/or promoting proliferation of intestinal epithelium by administering an Interferon (IFN) ? ligand or an IFN?, receptor agonist to a subject in need thereof. Preferred methods utilising an IFN? receptor agonist concern preventing or treating a gastrointestinal disease, disorder or condition, such as GVHD, inflammatory bowel disease and autoimmune and therapy-related enterocolitis.

Abstract: Provided herein are methods and compositions related to the selection T cells and/or subjects for adoptive immunotherapy based on the expression of one or more biomarkers.

Abstract: Anti-GAL9 antibody constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.

Abstract: Provided are methods for determining or predicting the diagnosis, prognosis, treatment and therapeutic efficacy of melanoma in a subject, which include evaluating the expression level of one or more miRNA biomarkers including miRNA-4487, miRNA-4706, miRNA-4731 and fragments or variants thereof as an indication of whether the subject may have, or be predisposed to, melanoma.

Abstract: Provided herein are immunogenic polypeptides, compositions, and methods related to the development of CMV-specific prophylactic and/or therapeutic immunotherapy based on T cell epitopes (e.g., CMV epitopes) that are recognized by cytotoxic T cells (CTLs) and can be employed in the prevention and/or treatment of CMV infection, reactivation, and/or disease (e.g., CMV-associated end organ disease), especially in solid organ transplant recipients.

Abstract: Provided herein are isolated alpha and beta chains of a T-cell receptor (TCR) that is specific for an EBV antigen. Also described herein are TCRs having said alpha and beta chains and methods of making and using same, such as cellular immunotherapy in subjects having an EBV-associated disease, disorder or condition.

Abstract: This invention relates generally to biomarkers that are useful for determining whether a subject with cancer is likely to respond to cancer therapy. The invention therefore relates to methods, kits and compositions for determining whether a subject is likely to respond to cancer therapy, and to methods of treatment based on a determination that a subject with cancer is likely to respond to cancer therapy. The invention also relates to methods for sensitizing a subject with cancer to cancer therapy.

Abstract: An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens.

Abstract: The present disclosure relates to methods and systems for assessing the risk of glaucoma in a subject. In certain embodiments, the present disclosure provide a method of assessing the risk of primary open angle glaucoma in a subject, the method comprises determining a risk score for primary open angle glaucoma in the subject on the basis of the genetic content of the subject at a plurality of selected genetic loci or markers and thereby assessing the risk of primary open angle glaucoma in the subject, wherein the selected genetic loci or markers comprise (i) genetic loci or markers having an association with glaucoma, and/or (ii) genetic loci or markers having an association with increased intraocular pressure, and/or (iii) genetic loci or markers having an association with an increased vertical cup to disk ratio, and/or (iv) genetic loci or markers having an association with a multi-trait test of glaucoma, intraocular pressure and vertical cup to disc ratio. Other embodiments are described.

Abstract: A method of reducing or relieving immune inhibition in a mammal includes the step of at least partly inhibiting or reducing CD96 activity in one or more cells of the mammal to thereby relieve immune inhibition and/or enhance or restore immune surveillance in the mammal. Typically, inhibiting or reducing CD96 activity does not include, or depend upon, killing of CD96-expressing cells in the mammal. The method relieves immune inhibition and/or enhances or restores immune surveillance in the mammal to thereby treat or prevent cancer or cancer metastasis and/or a viral infection in the mammal. Also provided is a method of screening, designing, engineering or otherwise producing a CD96-inhibitory agent that relieves immune inhibition and/or enhances or restores immune surveillance in a mammal.

Abstract: Methods and an apparatus are provided, which may be used for determining the prognosis and/or diagnosis of a subject demonstrating burst suppression, whereby the subject has or is at risk of developing brain damage. In particular, the methods and apparatus determine the prognosis and/or diagnosis through the detection of bursts from a reading of electrical and/or electromagnetic activity of the subject's brain, such as an electroencephalogram (EEG), and subsequent analysis of one or more burst metrics derived therefrom.

Abstract: Disclosed are methods for identifying immunogenic peptides, and tools and/or reagents to be used in those methods. More specifically, the invention relates to combinatorial peptide library screening for synthetic antigenic peptides recognized by natural T-cell receptors.